2,3-Dimethoxyquinone Compositions for Preventing Diabetic Retinopathy
Summary
USPTO published patent application US20260108483A1 on April 23, 2026, covering methods, compositions, and kits containing substituted 2,3-dimethoxyquinone (Formula I) or a pharmaceutically acceptable salt for preventing progression of diabetic retinopathy, diabetic macular edema, and related retinal disorders. The application names four inventors: Mitchell George Brigell, Ronil Ajaykumar Patel, Jay Stuart Pepose, and Mina Sooch. Filed July 24, 2025 under application number 19279680, the invention is classified under CPC codes A61K 31/192, A61P 9/10, and A61P 27/02.
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 193 changes logged to date.
What changed
USPTO published patent application US20260108483A1 for methods and compositions using substituted 2,3-dimethoxyquinone (Formula I) as a therapeutic agent to prevent progression of diabetic retinopathy, diabetic macular edema, and other retinal disorders. The application discloses therapeutic compositions in kit form with specified CPC classifications A61K 31/192, A61P 9/10, and A61P 27/02.
Pharmaceutical and biotechnology companies developing ophthalmic or diabetes-related therapeutics may want to review this application for potential overlap with existing research programs. The publication does not constitute a granted patent and does not create enforceable exclusivity; however, it establishes a priority date of July 24, 2025 for the claimed compositions and methods.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS AND COMPOSITIONS FOR PREVENTING THE PROGRESSION OF DIABETIC RETINOPATHY AND RELATED CONDITIONS
Application US20260108483A1 Kind: A1 Apr 23, 2026
Inventors
Mitchell George Brigell, Ronil Ajaykumar Patel, Jay Stuart Pepose, Mina Sooch
Abstract
The invention provides methods, compositions, and kits containing a first therapeutic agent that is a substituted 2,3-dimethoxyquinone of Formula I, or a pharmaceutically acceptable salt thereof, for preventing the progression of diabetic retinopathy, diabetic macular edema, and/or other retinal disorders and/or other disorders.
CPC Classifications
A61K 31/192 A61P 9/10 A61P 27/02
Filing Date
2025-07-24
Application No.
19279680
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.